Skip to main content

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

Recruiting · Phase 3 · NCT07140783

Conditions: Vision Loss Night, Vision Disorders

At a glance

Research payments reported, 2025
$1.7M
U.S. investigators named
32
Sites paid
34
Planned or actual enrollment
580

About the trial

Sponsor
Opus Genetics, Inc
Tested
0.75% Phentolamine Ophthalmic Solution (drug), Placebo (drug)
Dates
Started 2025-09-02; completion 2027-08
Results posted
Not yet

The goal of this clinical trial is to learn if Phentolamine Ophthalmic Solution works to treat adults that have had keratorefractive surgery and have decreased visual acuity under mesopic conditions. It will also learn about the safety of Phentolamine Ophthalmic Solution. The main questions it aims to answer are: Researchers will compare Phentolamine Ophthalmic Solution to a placebo (a look-alike substance that contains no drug) to see if Phentolamine Ophthalmic Solution works to improve vision in low light conditions. Participants will: Take Phentolamine Ophthalmic Solution or a placebo drop every day for 2 weeks Visit the clinic once every week for 2 weeks for checkups and tests Keep a …

From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Oyster Point Pharma, Inc. reported $1.7M in research payments for this study in 2025 (188 payments).

Products named: Ryzumvi

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Eye Research Foundation $277,862
  • Piedmont Eye Center $218,368
  • Oculus Research $183,071
  • Global Research Management Inc $153,257
  • Mrb Eye Consultants, LLC $116,564
  • Durrie Vision $97,725
  • Gordon Schanzlin New Vision Institute $87,760
  • Northeast Eye Research Assoc $65,306
  • Eye Doctors of Arizona $64,082
  • Arizona Eye Center $47,574
  • West Bay Eye Associates $44,927
  • Segal Drug Trials, Inc $37,863
  • Wyse Eyecare, S.c. $32,313
  • Hoopes, Durrie, Rivera Research $25,662
  • Butchertown Clinical Trials $24,231
  • Zillian Clinical Research $23,858
  • Kannar Eye Center $21,450
  • Scripps Poway Eyecare & Optometry $20,602
  • Bergstrom Eye Research $17,896
  • Global Research Management, Inc. $16,514
  • Red River Research PArtners LLC $12,285
  • Hoopes Vision Research $10,784
  • Wolstan & Goldberg Eye Associates $10,408
  • Sight MD $8,056
  • International Research Center $7,812
  • California Eye Specialists Medical Group, Inc. $4,500
  • Levenson Eye Associates $4,094
  • Advancing Vision Research, LLC $3,210
  • Bowden Eye & Associates $3,000
  • Virdi Eye Clinic $3,000
  • Carolina Eyecare Physicians LLC $3,000
  • Center for Ophthalmic and Vision Research $2,000
  • Nvision Clinical Research, LLC $600
  • Empire Eye and Laser Center $600

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.